Traders Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was the target of unusually large options trading on Friday. Traders bought 9,112 call options on the stock. This represents an increase of 221% compared to the typical volume of 2,842 call options.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SRPT shares. Wedbush restated an “outperform” rating and set a $224.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. TheStreet upgraded Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Citigroup upped their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Royal Bank of Canada upped their price objective on Sarepta Therapeutics from $142.00 to $182.00 and gave the stock a “sector perform” rating in a report on Friday. Finally, Robert W. Baird upped their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $177.65.

Insider Buying and Selling

In related news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The transaction was disclosed in a document filed with the SEC, which is available through this link. 7.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Garde Capital Inc. bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth approximately $140,000. Cetera Investment Advisers raised its position in shares of Sarepta Therapeutics by 27.6% in the 1st quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company’s stock worth $1,552,000 after acquiring an additional 2,590 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. New Covenant Trust Company N.A. bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth approximately $32,000. Finally, Comerica Bank raised its position in shares of Sarepta Therapeutics by 489.4% in the 1st quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock worth $432,000 after acquiring an additional 2,770 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 30.1 %

Shares of SRPT stock opened at $160.72 on Friday. The stock has a market capitalization of $15.19 billion, a PE ratio of 1,461.09 and a beta of 0.96. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The business has a 50-day moving average of $125.56 and a 200 day moving average of $119.73. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. Sarepta Therapeutics’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.44) EPS. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.99 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.